Pentafuside. DP 178, T 20.
D000818:Animals; D019380:Anti-HIV Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology*; D002986:Clinical Trials as Topic; D015507:Drugs, Investigational / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology*; D000077560:Enfuvirtide; D015700:HIV Envelope Protein gp41; D015497:HIV-1 / Q000187:drug effects; D006207:Half-Life; D006801:Humans; D007273:Injections, Intramuscular; D007275:Injections, Intravenous; D007279:Injections, Subcutaneous; D051379:Mice; D016513:Mice, SCID; D010446:Peptide Fragments
D019380:Anti-HIV Agents; D015507:Drugs, Investigational; D015700:HIV Envelope Protein gp41; D010446:Peptide Fragments; D000077560:Enfuvirtide